Sunitinib versus imatinib dose escalation after failure of imatinib standard dose in patients with advanced Gastrointestinal stromal tumors – a real-world multi-center study

BACKGROUND: Whether to escalate imatinib dosage or directly switch to sunitinib in gastrointestinal stromal tumors (GISTs) failing on standard dose 400 mg/d of imatinib is still controversial. METHODS: We evaluated progression-free survival (PFS), overall survival (OS), and time to sunitinib failure...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Shaoqing, Liu, Xing, Guo, Xiaodan, Wu, Hui, Lu, Huishan, Pan, Zhizhong, Cai, Shirong, Wu, Xiaojun, Zhang, Xinhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950928/
https://www.ncbi.nlm.nih.gov/pubmed/36791510
http://dx.doi.org/10.1016/j.tranon.2023.101641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950928/
https://www.ncbi.nlm.nih.gov/pubmed/36791510
http://dx.doi.org/10.1016/j.tranon.2023.101641

Ejemplares similares